On November 6, 2019 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported the clinical and preclinical abstracts related to flotetuzumab, the Company’s investigational bispecific CD123 x CD3 DART molecule, to be presented at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition in Orlando, Florida, from December 7-10, 2019 (Press release, MacroGenics, NOV 6, 2019, View Source [SID1234553169]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to presenting updated data from the Phase 1 monotherapy study of flotetuzumab in patients with relapsed or refractory acute myeloid leukemia," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "The oral presentations will focus on patients with refractory AML, who represent an extremely challenging population to treat, and where we believe there may be an opportunity to address a significant unmet need with flotetuzumab."
Oral Presentations
Flotetuzumab, an Investigational CD123 x CD3 Bispecific DART Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Session Name: 613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease
Date: Monday, December 9, 2019
Session Time: 2:45 PM – 4:15 PM
Presentation Time: 2:45 PM
Location: Orange County Convention Center, Tangerine 3 (WF3-4)
Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123 × CD3 Bispecific DART Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML
Date: Sunday, December 8, 2019
Session Time: 12:00 PM – 1:30 PM
Presentation Time: 12:45 PM
Location: Orange County Convention Center, Valencia BC (W415BC)
Poster Presentations
Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific DART Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Date: Saturday, December 7, 2019
Presentation Time: 5:30 PM – 7:30 PM
Location: Orange County Convention Center, Hall B
Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid Leukemia
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Date: Saturday, December 7, 2019
Presentation Time: 5:30 PM – 7:30 PM
Location: Orange County Convention Center, Hall B
A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Date: Sunday, December 8, 2019
Presentation Time: 6:00 PM – 8:00 PM
Location: Orange County Convention Center, Hall B
The abstracts were published today on the ASH (Free ASH Whitepaper) website at View Source
Conference Call & Webcast
MacroGenics management and external guest speakers will host a conference call and audio webcast on Monday, December 9 at 8:00 P.M. ET to review the flotetuzumab data presented at the ASH (Free ASH Whitepaper) annual meeting and discuss ongoing clinical development plans.
To participate in the MacroGenics ASH (Free ASH Whitepaper) 2019 Conference Call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and provide the Conference ID: 3625435. A listen-only slide and audio webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company’s website at View Source A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days.